Approximately 40 million Americans are currently taking GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro, driving a 500% surge in national spending from $13.7 billion in 2018 to $71.7 billion in 2023, according to a poll by the Kaiser Family Foundation and healthcare data. Despite the massive adoption of these treatments, widespread misconceptions persist regarding their history, drug differences, insurance coverage hurdles, and how they interact with the body.
What Are GLP-1 Medications and Who Discovered Them?
GLP-1 stands for glucagon-like peptide-1, which Dr. Mihal Zilbermint, an endocrinologist at Johns Hopkins University, describes as a hormone made naturally in the body when we eat, with medications engineered as small molecules to mimic that natural process. Contrary to the belief that these drugs are entirely new, their foundational history dates back to the 1980s. Researchers Joel Habener and Svetlana Mojsov are credited with discovering the specific hormone that paved the way for GLP-1 development. In 1992, John Eng discovered a peptide called exendin-4 while studying Gila monster venom, which acted similarly to GLP-1 in the human body. That extensive research culminated in the Food and Drug Administration approving exenatide as the first GLP-1 medication in 2005.
Did you know? The first GLP-1 medication, exenatide, was approved by the FDA all the way back in 2005, long before brand names like Ozempic and Wegovy dominated mainstream headlines.
Comparing the Drugs: Semaglutide vs. Tirzepatide
While patients frequently lump all these medications together, distinct chemical and functional differences exist between them. Ozempic and Wegovy are semaglutides, meaning they function solely as a GLP-1, though Ozempic is prescribed for diabetes while Wegovy is designated for weight loss. In contrast, Mounjaro and Zepbound are tirzepatides, combining a GLP-1 with GIP, another gut hormone that assists with weight reduction. Mounjaro targets diabetes management, whereas Zepbound is approved for weight loss.
| Brand Name | Active Compound | Primary FDA Approval |
|---|---|---|
| Ozempic | Semaglutide | Diabetes |
| Wegovy | Semaglutide | Weight Loss |
| Mounjaro | Tirzepatide (GLP-1 + GIP) | Diabetes |
| Zepbound | Tirzepatide (GLP-1 + GIP) | Weight Loss |
Insurance Coverage Hurdles and Compounding Pharmacies
Accessing these drugs often depends heavily on a patient’s diagnosis and health insurance plan. For individuals diagnosed with type 2 diabetes, coverage is straightforward because research confirms the drugs effectively regulate blood sugar and reduce adverse outcomes. For overweight or obese patients—defined by the FDA as having a body mass index of 30 or higher—coverage gets complicated. Most major insurance providers require at least one comorbidity, such as hypertension or high cholesterol, and review claims case-by-case, frequently resulting in denials.
Insurance rejections drive many patients toward compounding pharmacies, where specialized facilities manufacture the medications directly rather than relying on major drug companies. Patients still need a valid doctor’s prescription for a compounded formula, but they bypass insurance hurdles since carriers do not foot the bill. Paul Pruitt, co-founder of SharkX, a company helping patients navigate expensive medications, notes that soaring demand paired with high costs creates a difficult financial environment. Because manufacturing processes are not widely disclosed, pricing relies primarily on what the market can bear, with monthly out-of-pocket costs ranging from $50 to well over $1,000.
How GLP-1s Work in the Body and Why Exercise Matters
GLP-1 medications operate through multiple biological pathways simultaneously. According to Dr. Zilbermint, they turn off brain hormones that trigger appetite, prompt the pancreas to release insulin when blood glucose spikes, reduce glucagon hormones that govern blood sugar, and slow the movement of food through the stomach and intestines. These combined actions cause patients to consume fewer calories and achieve better blood sugar regulation.
However, relying solely on the medication without lifestyle changes can lead to unintended consequences. Without physical activity, patients risk losing critical muscle mass alongside fat tissue. Dr. Zilbermint emphasizes that GLP-1s must be part of a comprehensive strategy incorporating nutrition and physical activity—such as lifting weights at home or joining online exercise classes—to preserve muscle while dropping pounds. Beyond weight and diabetes management, researchers are actively investigating the potential benefits of GLP-1s on heart attacks, strokes, kidney failure, liver failure, certain cancers, sleep apnea, and dementia, though users commonly report side effects like nausea, cramping, bloating, diarrhea, and constipation.
Pro Tip: Talk thoroughly with an endocrinologist or primary care physician to map out a nutrition and resistance training plan before starting a GLP-1 prescription, ensuring you protect your lean muscle mass while losing weight.
Frequently Asked Questions
What does GLP-1 stand for?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the human body when eating.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but Ozempic is prescribed to treat diabetes, while Wegovy is approved for weight loss.
Why are GLP-1 medications so expensive?
High demand coupled with opaque manufacturing processes allows drug prices to scale according to what the market can bear, with costs ranging from $50 to over $1,000 per month.
Do GLP-1 drugs cause muscle loss?
Yes, taking these medications without incorporating adequate nutrition and strength training can cause patients to lose muscle tissue alongside fat.
Join the Conversation: Are you or a loved one navigating insurance approvals or compounding pharmacies for a GLP-1 prescription? Leave a comment below, share this article with your network, or subscribe to our newsletter for more healthcare updates.
Worth a look